<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>Evan Albright — Digest tagged &quot;export-control&quot;</title><description>Digest issues tagged #export-control.</description><link>https://www.evanalbright.com/</link><language>en-us</language><item><title>AbbVie buys Apogee for $11B as pharma&apos;s $123B deal wave rolls on</title><link>https://www.evanalbright.com/digest/2026-06-22/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-06-22/</guid><description>AbbVie agreed to acquire Apogee Therapeutics for nearly $11 billion, the latest in a pharma M&amp;A wave that has totaled $123 billion in 2026 deals so far. Definium&apos;s LSD therapy met its primary endpoint in a Phase 3 trial for major depression, and the FDA reversed a four-month-old rejection of Regenxbio&apos;s gene therapy for Hunter syndrome. In AI, Samsung deployed ChatGPT Enterprise and Codex to employees worldwide in one of OpenAI&apos;s largest enterprise rollouts, while Nathan Lambert and Kevin Xu argued that banning open-source AI would damage US interests. Patrick Boyle examined how SpaceX humiliated Wall Street and Cuba announced its most sweeping economic reforms in decades, including private banking and the end of fuel subsidies.</description><pubDate>Mon, 22 Jun 2026 00:00:00 GMT</pubDate><category>ai</category><category>pharma</category><category>economy</category><category>software</category><category>healthtech</category><category>open-weights</category><category>m&amp;a</category><category>export-control</category><category>psychedelics</category><category>fda</category><category>spacex</category><category>llm</category><category>enterprise</category><category>biotech</category><category>cuba</category><category>codex</category><category>deployment</category><category>evals</category><category>cybersecurity</category><category>agents</category><category>benchmarks</category><category>open-source</category><category>policy</category><category>geopolitics</category><category>claude</category><category>safety</category><category>identity</category><category>anthropic</category><category>cost</category><category>models</category><category>cloudflare</category><category>infrastructure</category><category>software-engineering</category><category>glm</category><category>chinese-models</category><category>security</category><category>sqlite</category><category>tools</category><category>database</category><category>mcp</category><category>architecture</category><category>fable</category><category>research</category><category>language</category><category>strategy</category><category>xai</category><category>competition</category><category>datasette</category><category>governance</category><category>conferences</category><category>architectures</category><category>transformers</category><category>debugging</category><category>training</category><category>whisper</category><category>fine-tuning</category><category>lora</category><category>jepa</category><category>vision</category><category>events</category><category>community</category><category>attention</category><category>kernels</category><category>voice</category><category>optimization</category><category>deno</category><category>runtime</category><category>desktop</category><category>startups</category><category>labor</category><category>fraud</category><category>sovereign-ai</category><category>scaling</category><category>theory</category><category>web</category><category>seo</category><category>standards</category><category>rust</category><category>graphics</category><category>imaging</category><category>civil-society</category><category>inference</category><category>javascript</category><category>python</category><category>data</category><category>migrations</category><category>engineering</category><category>immunology</category><category>abbvie</category><category>dealmaking</category><category>financing</category><category>depression</category><category>clinical-trials</category><category>phase3</category><category>gene-therapy</category><category>rare-disease</category><category>pediatrics</category><category>nih</category><category>health-equity</category><category>funding</category><category>atopic-dermatitis</category><category>lsd</category><category>diversity</category><category>deals</category><category>mental-health</category><category>cmo</category><category>pipeline</category><category>letters</category><category>opinion</category><category>style</category><category>terminology</category><category>industry</category><category>personnel</category><category>disability</category><category>grants</category><category>emergency-medicine</category><category>addiction</category><category>healthcare</category><category>drug-discovery</category><category>r&amp;d</category><category>sanofi</category><category>ipo</category><category>business</category><category>markets</category><category>private-equity</category><category>valuation</category><category>china</category><category>reform</category><category>emerging-markets</category><category>fintech</category><category>payments</category><category>banking</category><category>tax-policy</category><category>economics</category><category>tcja</category><category>employment</category><category>california</category><category>regulation</category><category>demographics</category><category>europe</category><category>religion</category><category>books</category><category>recommendations</category><category>consumer-behavior</category><category>technology</category><category>unintended-consequences</category><category>capitalism</category><category>latin-america</category><category>music</category><category>globalization</category><category>aesthetics</category><category>philosophy</category><category>links</category><category>national-identity</category><category>japan</category><category>poetry</category><category>sweden</category><category>media</category><category>writing</category><category>influence</category><category>mexico</category><category>growth</category><category>trade</category><category>covid</category><category>bubbles</category><category>venture-capital</category></item><item><title>GLM-5.2 drops under MIT license as Fable 5 export control dispute deepens</title><link>https://www.evanalbright.com/digest/2026-06-18/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-06-18/</guid><description>Z.ai released GLM-5.2, a 753-billion-parameter open-weights LLM under MIT license, which Simon Willison called the most powerful text-only open-weights model available. Separately, a White House report on the Fable 5 export control jailbreak drew pushback from cybersecurity expert Kate Moussouris, who said the restriction harms US cyber defense. OpenAI and Molecule.one published results from a near-autonomous AI chemist using GPT-5.4 that improved a challenging medicinal chemistry reaction. In pharma, nitazene overdose deaths confirmed by the CDC rose from 27 in 2020 to 409 in 2024, while the FTC and four state AGs sued WPATH over its gender-affirming care standards. Tyler Cowen flagged new research showing AI-native startups are organized differently from conventional venture-backed firms, drawing on Y Combinator data from 2020 to 2024.</description><pubDate>Thu, 18 Jun 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>llm</category><category>open-weights</category><category>glm</category><category>export-control</category><category>fable5</category><category>nitazenes</category><category>opioids</category><category>antitrust</category><category>wpath</category><category>deepseek</category><category>agents</category><category>health-ai</category><category>dementia</category><category>vaccines</category><category>ai-native-firms</category><category>open-source</category><category>inference</category><category>security</category><category>governance</category><category>policy</category><category>drug-discovery</category><category>chemistry</category><category>safety</category><category>evals</category><category>benchmarks</category><category>science</category><category>software-engineering</category><category>economics</category><category>productivity</category><category>imaging</category><category>medtech</category><category>computer-vision</category><category>mechanistic-interpretability</category><category>probing</category><category>research</category><category>openai</category><category>financials</category><category>business</category><category>nvidia</category><category>models</category><category>chinese-models</category><category>analysis</category><category>deepmind</category><category>interpretability</category><category>claude</category><category>newsletter</category><category>training</category><category>scaling</category><category>strategy</category><category>fable</category><category>trends</category><category>cs</category><category>qwen</category><category>local-models</category><category>coding</category><category>local-ai</category><category>meta</category><category>labor</category><category>management</category><category>sdk</category><category>cloudflare</category><category>runtime</category><category>zero-trust</category><category>network</category><category>infrastructure</category><category>browsers</category><category>vm</category><category>china</category><category>http</category><category>standards</category><category>protocol</category><category>api</category><category>engineering</category><category>email</category><category>ml</category><category>observability</category><category>tools</category><category>grapheneos</category><category>drm</category><category>git</category><category>vcs</category><category>cicd</category><category>devops</category><category>os</category><category>systems</category><category>synthetic-drugs</category><category>overdose</category><category>cdc</category><category>public-health</category><category>hhs</category><category>rfk</category><category>congress</category><category>infant-formula</category><category>botulism</category><category>food-safety</category><category>fda</category><category>ftc</category><category>gender-affirming-care</category><category>mental-health</category><category>funding</category><category>addiction</category><category>biotech</category><category>regulation</category><category>drug-approval</category><category>nih</category><category>diversity</category><category>higher-education</category><category>fraud</category><category>global-health</category><category>glp1</category><category>vaccine</category><category>formula</category><category>hospitals</category><category>healthcare</category><category>education</category><category>clinical</category><category>chronic-disease</category><category>energy</category><category>environment</category><category>doj</category><category>roundup</category><category>cancer</category><category>clinical-trials</category><category>oncology</category><category>accountability</category><category>startups</category><category>venture-capital</category><category>organization</category><category>neuroscience</category><category>politics</category><category>foreign-policy</category><category>iran</category><category>trump</category><category>geopolitics</category><category>europe</category><category>competition</category><category>housing</category><category>zoning</category><category>real-estate</category><category>fed</category><category>roblox</category><category>gaming</category><category>demographics</category><category>latin-america</category><category>links</category><category>marriage</category><category>social-media</category><category>psychology</category><category>markets</category><category>ipo</category><category>surveillance</category><category>signaling</category><category>agriculture</category><category>commodities</category></item><item><title>US suspends Fable 5 access for foreign nationals as export controls hit frontier AI</title><link>https://www.evanalbright.com/digest/2026-06-15/</link><guid isPermaLink="true">https://www.evanalbright.com/digest/2026-06-15/</guid><description>The US government issued an export control directive suspending all access to Claude Fable 5 and Mythos 5 for foreign nationals, a move that rattled the AI industry and prompted Tyler Cowen to note the equilibrium was hard to solve for. Separately, Arvind Narayanan and Sayash Kappoor published a detailed argument that software engineers won&apos;t be replaced by AI, citing task fragmentation and the compounding cost of errors. The FDA approved Sanofi&apos;s teplizumab for children with stage 3 type 1 diabetes after it cleared a dispute between career staff and political appointees. Noah Smith asked whether Chinese corporate debt could zombify the economy, while Patrick Boyle examined how SpaceX humiliated Wall Street by retaining founder control across 25x more fundraising than typical startups.</description><pubDate>Mon, 15 Jun 2026 00:00:00 GMT</pubDate><category>ai</category><category>software</category><category>pharma</category><category>healthtech</category><category>economy</category><category>claude</category><category>fable5</category><category>export-control</category><category>governance</category><category>policy</category><category>fda</category><category>drug-approval</category><category>spacex</category><category>ipo</category><category>china</category><category>prediction-markets</category><category>medicare</category><category>drug-shortage</category><category>llm</category><category>evals</category><category>agents</category><category>safety</category><category>syphilis</category><category>penicillin</category><category>medicaid</category><category>agi</category><category>software-engineering</category><category>jobs</category><category>economics</category><category>gdp</category><category>labor</category><category>macroeconomics</category><category>clinical</category><category>health-ai</category><category>benchmarks</category><category>education</category><category>training</category><category>nvidia</category><category>open-source</category><category>commoditization</category><category>analysis</category><category>trends</category><category>forecasting</category><category>rag</category><category>knowledge-graphs</category><category>reasoning</category><category>mlops</category><category>edge-ml</category><category>robotics</category><category>cnns</category><category>architecture</category><category>efficiency</category><category>cv</category><category>healthcare</category><category>applications</category><category>security</category><category>curl</category><category>engineering</category><category>apple</category><category>sdk</category><category>on-device</category><category>tools</category><category>provenance</category><category>formal-methods</category><category>programming</category><category>verification</category><category>codex</category><category>model-routing</category><category>reliability</category><category>cloudflare</category><category>kafka</category><category>postgres</category><category>scaling</category><category>performance</category><category>editor</category><category>productivity</category><category>tooling</category><category>drm</category><category>standards</category><category>epub</category><category>windows</category><category>authentication</category><category>user-experience</category><category>archival</category><category>web</category><category>finance</category><category>marketplace</category><category>auth</category><category>platform</category><category>storage</category><category>pricing</category><category>workflows</category><category>nitro</category><category>serverless</category><category>models</category><category>api</category><category>inference</category><category>collaboration</category><category>sharing</category><category>diabetes</category><category>pediatrics</category><category>sanofi</category><category>maternal-health</category><category>public-health</category><category>disability</category><category>caregivers</category><category>funding</category><category>ebola</category><category>who</category><category>drc</category><category>outbreak</category><category>crispr</category><category>gene-editing</category><category>obesity</category><category>cancer</category><category>drug-discovery</category><category>biotech</category><category>investment</category><category>abridge</category><category>drug-pricing</category><category>cms</category><category>history</category><category>nutrition</category><category>california</category><category>food</category><category>antibiotics</category><category>supply-chain</category><category>state-legislation</category><category>evidence</category><category>psychiatry</category><category>autism</category><category>stigma</category><category>medical-education</category><category>careers</category><category>demographics</category><category>hiring</category><category>industry</category><category>newsletter</category><category>venture-capital</category><category>musk</category><category>capital-markets</category><category>debt</category><category>corporate</category><category>growth</category><category>sports</category><category>regulation</category><category>betting</category><category>europe</category><category>brazil</category><category>agriculture</category><category>immigration</category><category>data</category><category>geopolitics</category><category>psychology</category><category>research</category><category>film</category><category>culture</category><category>cities</category><category>science</category><category>politics</category><category>links</category><category>roundup</category><category>philosophy</category><category>science-fiction</category><category>retail</category><category>service-sector</category><category>mexico</category><category>inflation</category><category>innovation</category><category>trade</category><category>strategy</category><category>bubbles</category><category>space</category><category>manufacturing</category><category>satellites</category><category>business-models</category></item></channel></rss>